Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis
Diseases and Conditions Researched
Cystic Fibrosis
What is the purpose of this trial?
Cystic Fibrosis (CF) is a fatal, recessive genetic disorder characterized by progressive inflammation and lung damage. It is unclear whether current treatment strategies, which focus on detection and eradication of pathogenic microorganisms in the lung, are the best way to prevent the initiation of early inflammation and lung damage. This study asks how early acquisition of microbial flora occurs in infants with CF and healthy baby controls, and whether this process initiates or influences early inflammation and clinical disease progression in CF.
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Yale University |
|---|---|
| Dates: | August 6, 2012 |
| Last Updated: | August 6, 2012 |
| Study HIC#: | 1206010476 |
| Clinicaltrials.gov ID: | NCT01661491 |
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.